Physician profile
Matthew Lee Abrell
NPI 1164917167
$1,713.20
in general payments reported to CMS, 2019-2025
26 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2021: $669 · 2022: $132 · 2023: $81.12 · 2024: $200 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $653.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $492.52 | 2021-2025 | Charlotte, Augment Injectable, Ortholoc 3di |
| Bioventus LLC | $145.90 | 2021-2022 | |
| Zimmer Biomet Holdings, INC. | $111.17 | 2021 | |
| Organogenesis INC. | $93.00 | 2019 | |
| Convatec INC. | $91.18 | 2024-2025 | |
| Horizon Therapeutics Plc | $86.08 | 2019 | |
| Anika Therapeutics, INC. | $74.31 | 2021 | |
| Smith+Nephew, INC. | $55.78 | 2024 | Oasis, Grafix Pl, Collagenase Santyl |
| Kci USA, INC. | $55.07 | 2022-2023 | V.A.C. Veraflo, Prevena |
| Abbvie INC. | $54.04 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $52.59 | 2019 | |
| Nevro Corp. | $42.93 | 2021 | |
| In2bones USA, LLC | $42.18 | 2021 | |
| Orthofix Medical, INC. | $39.52 | 2023-2025 | Physio-Stim |
| Treace Medical Concepts, INC. | $34.42 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $31.81 | 2025 | |
| Globus Medical, INC. | $30.88 | 2025 | Senza |
| Paragon 28, INC. | $27.60 | 2019 | |
| Sequel Med Tech, LLC | $25.50 | 2025 | Twiist |
| Novo Nordisk INC | $21.21 | 2025 | Rybelsus, Ozempic |
| Integra Lifesciences Corporation | $20.50 | 2022 | |
| Teleflex LLC | $18.80 | 2025 | Barrigel |
| Teva Pharmaceuticals USA, INC. | $18.03 | 2025 | Austedo Xr |
| Sanara Medtech INC. | $16.94 | 2024 | Celleraterx |
| Bayer Healthcare Pharmaceuticals INC. | $16.49 | 2025 | |
| Madrigal Pharmaceuticals | $14.75 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Abrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.